Artículos de revistas
The Alzheimer`s Association external quality control program for cerebrospinal fluid biomarkers
Fecha
2011Registro en:
ALZHEIMERS & DEMENTIA, v.7, n.4, p.386-395, 2011
1552-5260
10.1016/j.jalz.2011.05.2243
Autor
MATTSSON, Niklas
ANDREASSON, Ulf
PERSSON, Staffan
ARAI, Hiroyuki
BATISH, Sat Dev
BERNARDINI, Sergio
BOCCHIO-CHIAVETTO, Luisella
BLANKENSTEIN, Marinus A.
CARRILLO, Maria C.
CHALBOT, Sonia
COART, Els
CHIASSERINI, Davide
CUTLER, Neal
DAHLFORS, Gunilla
DULLER, Stefan
FAGAN, Anne M.
FORLENZA, Orestes
FRISONI, Giovanni B.
GALASKO, Douglas
GALIMBERTI, Daniela
HAMPEL, Harald
HANDBERG, Aase
HENEKA, Michael T.
HERSKOVITS, Adrianna Z.
HERUKKA, Sanna-Kaisa
HOLTZMAN, David M.
HUMPEL, Christian
HYMAN, Bradley T.
IQBAL, Khalid
JUCKER, Mathias
KAESER, Stephan A.
KAISER, Elmar
KAPAKI, Elisabeth
KIDD, Daniel
KLIVENYI, Peter
KNUDSEN, Cindy S.
KUMMER, Markus P.
LUI, James
LLADO, Albert
LEWCZUK, Piotr
LI, Qiao-Xin
MARTINS, Ralph
MASTERS, Colin
MCAULIFFE, John
MERCKEN, Marc
MOGHEKAR, Abhay
MOLINUEVO, Jose Luis
MONTINE, Thomas J.
NOWATZKE, William
O`BRIEN, Richard
OTTO, Markus
PARASKEVAS, George P.
PARNETTI, Lucilla
PETERSEN, Ronald C.
PRVULOVIC, David
REUS, Herman P. M. de
RISSMAN, Robert A.
SCARPINI, Elio
STEFANI, Alessandro
SOININEN, Hilkka
SCHROEDER, Johannes
SHAW, Leslie M.
SKINNINGSRUD, Anders
SKROGSTAD, Brith
SPREER, Annette
TALIB, Leda
TEUNISSEN, Charlotte
TROJANOWSKI, John Q.
TUMANI, Hayrettin
UMEK, Robert M.
BROECK, Bianca Van
VANDERSTICHELE, Hugo
VECSEI, Laszlo
VERBEEK, Marcel M.
WINDISCH, Manfred
ZHANG, Jing
ZETTERBERG, Henrik
BLENNOW, Kaj
Institución
Resumen
Background: The cerebrospinal fluid (CSF) biomarkers amyloid beta (A beta)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer`s disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer`s Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program. Methods: The program is open for laboratories using commercially available kits for A beta, T-tau, or P-tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Molndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples. Results: Forty laboratories participated. Twenty-six used INNOTEST enzyme-linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO-BIA AlzBio3 kit (both measure A beta-(1-42), P-tau(181P), and T-tau), and 5 used Mesa Scale Discovery with the A beta triplex (A beta N-42, A beta N-40, and A beta N-38) or T-tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within-laboratory precisions differed considerably between biomarkers within individual laboratories. Conclusions: Measurements of CSF AD biomarkers show large between-laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers. (C) 2011 The Alzheimer`s Association. All rights reserved.